- PharmEasy’s valuation is projected to drop by 90%, going from $5.5bn to a mere $500-600m.
- Despite this, investors remain confident and expect the company to recover over the next two years, buoyed by profitable acquisitions such as Thyrocare.
- However, corporate debts accumulated by PharmEasy, including a $285m loan from Goldman Sachs, bring an additional level of financial uncertainty.
Menu
